放疗联合瑞卢戈利治疗局限期或晚期前列腺癌男性的疗效与安全性
这项多中心事后分析纳入2项随机临床试验中接受放疗的局限期或晚期前列腺癌患者,评估口服促性腺激素释放激素拮抗剂瑞卢戈利联合放疗的疗效与安全性。瑞卢戈利在短期和长期ADT中均达到高去势率,快速恢复睾酮,且未发现新的安全性问题。
要点
- 瑞卢戈利联合放疗在短期ADT中去势率达95%(95%CI 87.1%-99.0%)。
- 瑞卢戈利联合放疗在长期ADT中去势率达97%(95%CI 90.6%-99.0%)。
- 瑞卢戈利组与亮丙瑞林组去势抵抗无生存差异(HR 0.97;95%CI 0.35-2.72;P=0.62)。
核心结论
- 2项随机临床试验结果表明,瑞卢戈利在接受放疗的局限期或晚期前列腺癌患者中快速达到持续去势。
- 瑞卢戈利与放疗联合使用未发现新的安全性问题。
研究设计与样本
- 多中心事后分析,纳入2项随机临床试验中接受放疗的局限期或晚期前列腺癌患者。
- 短期(24周)ADT组103例,来自2014年至2015年的2期试验(瑞卢戈利 vs 地加瑞克)。
- 长期(48周)ADT组157例,来自2017年至2019年的3期HERO试验子集(瑞卢戈利 vs 醋酸亮丙瑞林)。
- 共260例患者,其中164例(63.1%)接受瑞卢戈利。
- 数据于2022年11月分析。
主要发现
- 短期ADT中瑞卢戈利去势率95%(95%CI 87.1%-99.0%),长期ADT中去势率97%(95%CI 90.6%-99.0%)。
- 短期瑞卢戈利治疗后12周,34例(52%)睾酮恢复至基线或≥280 ng/dL。
- 长期ADT后90天,评估睾酮恢复的子集中,瑞卢戈利组平均(SD)睾酮310.5(122.4)ng/dL(n=15),醋酸亮丙瑞林组53.0 ng/dL(n=8)。
- 瑞卢戈利组与醋酸亮丙瑞林组去势抵抗无生存期无统计学差异(HR 0.97;95%CI 0.35-2.72;P=0.62)。
- 短期或长期瑞卢戈利中3级及以上不良事件(头痛、高血压、心房颤动)不常见(低于5%)。
关键数值与推荐
- 去势率定义为第5周至第25周(短期ADT)或第5周至第49周(长期ADT)所有计划访视时睾酮<50 ng/dL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Combination androgen deprivation therapy (ADT) with radiotherapy is commonly used for patients with localized and advanced prostate cancer. OBJECTIVE: To assess the efficacy and safety of the oral gonadotropin-releasing hormone antagonist relugolix with radiotherapy for treating prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: This multicenter post hoc analysis of patients with localized and advanced prostate cancer receiving radiotherapy in 2 randomized clinical trials (a phase 2 trial of relugolix vs degarelix, and a subset of the phase 3 HERO trial of relugolix vs leuprolide acetate) included men who were receiving radiotherapy and short-term (24 weeks) ADT (n = 103) from 2014 to 2015 and men receiving radiotherapy and longer-term (48 weeks) ADT (n = 157) from 2017 to 2019. The data were analyzed in November 2022. INTERVENTIONS: Patients receiving short-term ADT received relugolix, 120 mg, orally once daily (320-mg loading dose) or degarelix, 80 mg, 4-week depot (240-mg loading dose) for 24 weeks with 12 weeks of follow-up. Patients receiving longer-term ADT received relugolix, 120 mg, orally once daily (360-mg loading dose) or leuprolide acetate injections every 12 weeks for 48 weeks, with up to 90 days of follow-up. MAIN OUTCOMES AND MEASURES: Castration rate (testosterone level <50 ng/dL [to convert to nmol/L, multiply by 0.0347) at all scheduled visits between weeks 5 and 25 for patients receiving short-term ADT and weeks 5 and 49 for patients receiving longer-term ADT. RESULTS: Of 260 patients (38 Asian [14.6%], 23 Black or African American [8.8%], 21 Hispanic [8.1%], and 188 White [72.3%] individuals), 164 (63.1%) received relugolix. Relugolix achieved castration rates of 95% (95% CI, 87.1%-99.0%) and 97% (95% CI, 90.6%-99.0%) among patients receiving short-term and longer-term ADT, respectively. Twelve weeks post-short-term relugolix, 34 (52%) achieved testosterone levels to baseline or more than 280 ng/dL. Ninety days post longer-term ADT, mean (SD) testosterone levels were 310.5 (122.4) (106.7) ng/dL (relugolix; n = 15) vs 53.0 ng/dL (leuprolide acetate; n = 8) among the subset assessed for testosterone recovery. Castration resistance-free survival was not statistically different between the relugolix and leuprolide acetate cohorts (hazard ratio, 0.97; 95% CI, 0.35-2.72; P = .62). Adverse events grade 3 or greater for short-term or longer-term relugolix (headache, hypertension, and atrial fibrillation) were uncommon (less than 5%). CONCLUSIONS AND RELEVANCE: The results of these 2 randomized clinical trials suggest that relugolix rapidly achieves sustained castration in patients with localized and advanced prostate cancer receiving radiotherapy. No new safety concerns were identified when relugolix was used with radiotherapy.
引用
- Spratt DE, George DJ, Shore ND, et al. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. JAMA Oncol. 2024. PMID: 38451492. doi:10.1001/jamaoncol.2023.7279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。